Navigation Links
Among the Novel Oral Anticoagulants, Bayer/Janssen's Xarelto is Positioned To Be the Sales-Leading Therapy for Venous Thromboembolism (VTE)
Date:8/29/2013

BURLINGTON, Mass., Aug. 29, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that Bayer/Janssen's Xarelto will be the sales-leading therapy among the novel oral anticoagulants in the combined venous thromboembolism (VTE) markets. Xarelto benefits from its first-to-market advantage for VTE treatment/secondary prophylaxis, the removal of the need for bridging with a low-molecular-weight heparin in the VTE treatment/secondary prophylaxis setting and once-daily dosing. Bristol-Myers Squibb/Pfizer's Eliquis will be Xarelto's closest competitor, but its later launch in both the VTE primary prophylaxis and VTE treatment/secondary prophylaxis markets, as well as its twice-daily dosing, will likely limit its sales relative to Xarelto during the 2012 to 2022 forecast period.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The Pharmacor advisory service entitled Venous Thromboembolism forecasts that the combined markets for drugs used for both VTE primary prophylaxis and VTE treatment/secondary prophylaxis will grow to $7.3 billion in 2022 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The novel oral anticoagulants are forecast to continue to gain market share at the expense of low-molecular-weight heparins (LMWHs) for VTE prevention following orthopedic surgery. Uptake is higher in Europe where a greater number of novel oral anticoagulants are available for this indication. However, despite this increased uptake, the LMWHs remain the overall market leader in the major markets covered in the report; along with vitamin K antagonists (VKAs), LMWHs continue to dominate the VTE/secondary prophylaxis market, where Xarelto is the only novel oral anticoagulant to have gained approval.

The report also finds that while the failure of the novel oral anticoagulants investigated in clinical trials for VTE primary prophylaxis in the medically ill will limit the growth potential of the VTE market, the overall market will benefit from increased physician awareness of the need for VTE primary prophylaxis following non-orthopedic surgery. However, the main growth driver for the VTE market will be the anticipated launches of the novel oral anticoagulants for VTE treatment/secondary prophylaxis, as their use at the expense of VKAs will mark a paradigm shift in standard treatment practices during the forecast period.

"The anticipated launches of Eliquis, Boehringer Ingelheim's Pradaxa and Daiichi Sankyo's Lixiana for VTE treatment/secondary prophylaxis, along with the previously-approved Xarelto will drive growth of the VTE market through 2022," said Decision Resources Analyst Eamonn O'Connor, Ph.D. "Growth opportunities for these agents will be restricted to the treatment/secondary prophylaxis market, owing to these agents' inability, to date, to gain a primary prophylaxis label outside of the orthopedic surgery setting."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Prem Reddy Named Among Most Influential Physician Executives in Nation
2. Brain Research Foundation Announces Grant To Study Concussive Events Among Grade School Children
3. Imaging Healthcare Specialists Among the First in the Nation to Offer Imaging Diagnosis for Alzheimers Disease
4. Advanced Radiology Among the First in the U.S. to Offer New Alzheimers Disease Tracer
5. Social Norms, Life Changes and Increasing Pressures Contribute to Substance Abuse Among Adult Women
6. Frost & Sullivan: Miniaturization of Medical Devices Reduces Mortality Rates among Cardiac Dysrhythmia Patients
7. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
8. CBIS Releases Corporate Operational Guidance for 2013 as the Company Reorganizes to better meet the Growing Global Crisis Associated with Anti-Retroviral Drug Resistance among People with AIDS, as well as the Increasing Need for Patient Friendly Ski
9. Forbes Ranks SynCardia Among "Americas Most Promising Companies" for Second Straight Year
10. GNC NutriWater, COTYs Beyonce Pulse NYC, Swansons Super DPA Fish Oil, Among First SupplySide Insights Awards Finalists
11. Poorest U.S. States Rank Among Most Wasteful in Unnecessary Medication-Related Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Fla. , Dec. 5, 2016  Breckenridge ... into a multi-product marketing agreement with development and ... injectable products. Under the terms of this agreement, ... its label in the United States ... and one tentatively-approved ANDA. The products cover a ...
(Date:12/5/2016)... , December 5, 2016 According to a new ... and by Application - Global Opportunity Analysis and Industry Forecast, 2014 - 2022", ... expected to reach $5,255 million by 2022, growing at a CAGR of 6.4% ... more than four-fifths share. Continue Reading ... ...
(Date:12/5/2016)... Sanovas, Inc., a life science asset holding company ... wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed Intubation ... http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed annually ...
Breaking Medicine Technology:
(Date:12/6/2016)... , ... December 06, 2016 , ... TopConsumerReviews.com recently gave ... Mobility Scooters . , Mobility Scooters give freedom to people who need help getting ... others may be facing a long period of rehabilitation after an illness or accident. ...
(Date:12/5/2016)... ... 2016 , ... What: Shriners Hospitals for Children, with the help of Dimension ... using a video monitor and web-enabled camera. Santa visits with children through Dimension Data’s ... Christmas Wonderland, which is where the video connection to the North Pole will stream. ...
(Date:12/5/2016)... (PRWEB) , ... December 06, 2016 , ... For many ... Lithuanian poetry , both thick and thin. The beauty of the Lithuanian language ... Trafford Publishing). , In this poetry book, Zubinas lyrically explores all aspects of a ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... leading global lifestyle design firm kathy ireland® Worldwide for five additional years, announced ... entered into an exclusive licensing agreement three years ago to design and develop ...
(Date:12/5/2016)... (PRWEB) , ... December 05, ... ... strategic interoperability, today announced that the company will provide alerting technology to ... has been recently awarded $1.7 million in federal funds as the sole ...
Breaking Medicine News(10 mins):